Abstract:Objective To determine the population pharmacokinetics of valproic acid(VPA) and identify the factors that explained PK variability in Chinese epileptic children.Methods 390 steady-state serum concentration samples were collected totally.The plasma samples for VPA concentration were analyzed using automated fluorescence polarization method(FPIA) with monoclonal antibodies.In total,321 patients aged 1.8(0.1-13.6) years and weighted 11.5(2.6-84) kg with 390 trough concentrations were extracted.Total body weight,VPA daily dose,gender and comedication with clonazepam,topiramate,carbamazepine,phenobarbital and oxcarbazepine were considered as covariates.A decrease of OFV(from basic model to covariate model) by more than 6.63 was considered to be statistically significant(P0.01,df=1).An increase of OFV from the full model of at least 10.83(P0.001,df = 1) was used as the chosen criterion for retaining the covariate in the model.Pharmacokinetic modeling was performed using NONMEM program(version 6,level 1.1) complied with G77 Fortran.A one-compartment pharmacokinetic model with first-order absorption and elimination(subroutine ADVAN2 and TRANS2) was used to describe the concentration-time data.The first-order conditional estimation method with η-e interaction(FOCE-I) was used throughout the model-building procedure.Various statistical models describing the random residual variability were considered.The reliability and stability of the population pharmacokinetic model developed was further assessed by a nonparametric bootstrap procedure.During this process,each patient was randomly sampled with replacement from the original data set to form new data set containing the same number of patients as the original data set.Results The final model for VPA apparent clearance(CL/F),including age(years),CLO comedication and liver enzyme inducer(carbamazepine or phenobarbital) covariates with a significant influence on this parameter,was as follows: CL/F=0.223·(Age/1.8)0.353·1.22CLO·1.36LEI,V=13.0·(Total body weight/11.5) where CLO was 1 when co-medicated with clonazepam preparation,otherwise CLO was 0;LEI was 1 when co-medicated with carbamazepine or phenobarbital preparation.The typical values for CL/F and apparent volume of distribution(V/F) were 0.223 L·h-1 and 13.0 L,respectively.Interindividual variability(coefficient of variation) for CL/F was 34.3% for final model and 51.5% for basic model;The residual unexplained variability was 25.6 %.In a single attempt of 200 bootstrap analysis,6(3.0%) runs terminated due to rounding errors and were excluded in the analysis.The parameter(except V/F) estimates from nonparametric bootstrap procedure were comparable and within 5% of the estimates from NONMEM.Conclusions A population pharmacokinetic model was proposed to estimate the individual CL/F for paediatric patients receiving VPA in terms of patient′s age,and concomitant clonazepam,carbamazepine or phenobarbital,in order to establish a prior dosage regimens.

Investigation of influence of valproic acid, phenytoin, phenobarbital to relative clearance of carbamazepine and its epoxide metabolite

Change characteristics of blood drug concentrations of valproic acid combined with carbapenems

Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy

Applying Physiologically Based Pharmacokinetic Modeling to Interpret Carbamazepine's Nonlinear Pharmacokinetics and Its Induction Potential on Cytochrome P450 3A4 and Cytochrome P450 2C9 Enzymes

Population pharmacokinetics of valproic acid in adult Chinese epileptic patients and its application in an individualized dosage regimen

Establishment of Population Phamacokinetic Model of Valproic Acid in Chinese Epileptic Children

Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling

Development, Validation and Clinical Application of an Online-Spe-lc-hrms/ms for Simultaneous Quantification of Phenobarbital, Phenytoin, Carbamazepine, and Its Active Metabolite Carbamazepine 10,11-Epoxide.

Population Pharmacokinetics of Valproate in Chinese Children with Epilepsy.

CYP2C93/3 Gene Expression Affects the Total and Free Concentrations of Valproic Acid in Pediatric Patients with Epilepsy

Influence of acylpeptide hydrolase polymorphisms on valproic acid level in Chinese epilepsy patients

ABCB1 c.3435C > T and EPHX1 c.416A > G polymorphisms influence plasma carbamazepine concentration, metabolism, and pharmacoresistance in epileptic patients

The Influence of Cytochrome Oxidase CYP2A6, CYP2B6, and CYP2C9 Polymorphisms on the Plasma Concentrations of Valproic Acid in Epileptic Patients

Analysis of Serum Concentration of Carbamazepine in 381 Cases

Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients

Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy

Establishment of Population Pharmacokinetic Models with Valproic Acid in Different Age Groups of Chinese Epileptic Children

Population pharmacokinetics of topiramate in Chinese children with epilepsy

Factors affecting serum phenobarbital concentration changes in pediatric patients receiving elixir and powder formulations

Retrospective Analysis of Steady-State Sodium Valproate Plasma Concentrations in Chinese Patients With Bipolar Disorder: Impact of Demographic and Clinical Characteristics

Physiologically based pharmacokinetic modeling to predict maternal pharmacokinetics and fetal carbamazepine exposure during pregnancy